Opendata, web and dolomites

SULIPRO

A scientifically proven, safe, naturally derived drug for the effective treatment of liver damage - an innovative solution for a significant unmet medical need

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SULIPRO project word cloud

Explore the words cloud of the SULIPRO project. It provides you a very rough idea of what is the project "SULIPRO" about.

small    clinical    amount    shield    company    made    builds    proven    specialised    24    permanent    botanical    market    nash    unless    transplant    web    showing    stages    inflammation    safe    drugs    nafld    seriously    first    progress    successful    ing    functions    33    humans    patients    combination    otc    causing    price    amazon    scientifically    animal    disease    therapeutic    undergone    supplements    foods    private    drug    cirrhosis    death    consumers    26    food    million    expects    parallel    shops    funds    prescribed    treatment    non    diseases    fat    commercialised    online    steatohepatitis    financial    fatty    scarring    sulipro    trial    soy    counter    medical    natural    fda    alcoholic    oral    liver    models    prevalence    trials    population    impair    months    distributor    positive    compounds    maintains    raised    efficacy    affordable    once    approved    physician    pharmacies    preclude    demonstrating    eur   

Project "SULIPRO" data sheet

The following table provides information about the project.

Coordinator
NATURAL SHIELD ISRAEL 2016 LIMITED 

Organization address
address: AD GORDON 13
city: HERZLIYA
postcode: n.a.
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Project website https://natshield.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-02-01   to  2017-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    NATURAL SHIELD ISRAEL 2016 LIMITED IL (HERZLIYA) coordinator 50˙000.00

Map

Leaflet | Map data © OpenStreetMap contributors, CC-BY-SA, Imagery © Mapbox

 Project objective

Non-alcoholic fatty liver disease (NAFLD) is a condition in which fat builds up in the liver causing inflammation and eventually lead to permanent scarring (cirrhosis), which can seriously impair the liver’s ability to functions. NAFLD can progress to non-alcoholic steatohepatitis (NASH), and then to liver failure resulting in death unless there is a liver transplant. The prevalence of NAFLD in Europe is estimated to be between 26 and 33% of the general population. Currently, there is no available therapeutic treatment for patients with NAFLD and NASH. Natural Shield have developed a specialised oral therapeutic, called SULIPRO, which is a combination of soy derived compounds, that has been proposed as a novel scientifically proven safe treatment for patients in the early stages of NAFLD and NASH. Current drugs produced for liver diseases have a large amount of side effects and high financial costs that may preclude their long-term use in patients with NAFLD or the early stages of NASH. SULIPRO has already undergone positive clinical trials in animal models and successful Phase I clinical trials in humans showing demonstrating no side effects and high efficacy. The company now requires funding for a small Phase II trial. Once commercialised SULIPRO will be made available to consumers at an affordable price, as an over the counter (OTC) drug, available in shops/pharmacies and on the web, using an online distributor, such as Amazon. Natural Shield maintains its own research program involved in developing in parallel OTC food supplements, physician-prescribed medical foods, and FDA-approved botanical drugs. The company expects to reach the market with its first products within 24 months and thus far has raised over 5 million EUR in private funds.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SULIPRO" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SULIPRO" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

CLOSER (2019)

Childhood Leukemia: Overcoming distance between South America and Europe Regions

Read More  

PREFERABLE (2019)

Project on Exercise for Fatigue Eradication in Advanced Breast cancer to improve quality of life

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More